[Review] Novel therapies for malignant pleural mesothelioma

Malignant pleural mesothelioma is a rare cancer that is typically associated with exposure to asbestos. Patients with malignant pleural mesothelioma have poor outcomes with suboptimal therapeutic options and currently no treatment is curative. The standard frontline treatment, cisplatin plus pemetrexed chemotherapy, has only short and insufficient efficacy, and no validated treatment beyond first-line therapy is available. New therapeutic strategies are therefore needed. The addition of bevacizumab (an anti-VEGF antibody) combined with cisplatin plus pemetrexed has shown some promise.

Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Arnaud Scherpereel, Frederic Wallyn, Steven M Albelda, Camille Munck Tags: Review Source Type: research